AR111459A1 - Péptidos y combinaciones de los mismos para usar en una inmunoterapia contra cánceres - Google Patents

Péptidos y combinaciones de los mismos para usar en una inmunoterapia contra cánceres

Info

Publication number
AR111459A1
AR111459A1 ARP180100893A ARP180100893A AR111459A1 AR 111459 A1 AR111459 A1 AR 111459A1 AR P180100893 A ARP180100893 A AR P180100893A AR P180100893 A ARP180100893 A AR P180100893A AR 111459 A1 AR111459 A1 AR 111459A1
Authority
AR
Argentina
Prior art keywords
peptides
tumors
combinations
same
against cancer
Prior art date
Application number
ARP180100893A
Other languages
English (en)
Inventor
Sebastian Haen
Annika Nelde
Nico Trautwein
Marco Moreno Di
Markus Lffler
Daniel Kowalewski
Juliane Sarah Walz
Stefan Stevanovic
Hans-Georg Rammensee
Original Assignee
Immatics Biotechnologies Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immatics Biotechnologies Gmbh filed Critical Immatics Biotechnologies Gmbh
Publication of AR111459A1 publication Critical patent/AR111459A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)

Abstract

Péptidos, proteínas, ácido nucleicos y células de utilidad en métodos inmunoterapéuticos. En particular, la presente acta se relaciona con inmunoterapias contra el cáncer. Se relaciona además con epitopes de péptidos de células T asociados a tumores, solos o en combinación con otros péptidos asociados a tumores que pueden servir, por ejemplo, como ingredientes farmacéuticos activos en composiciones de vacunas que estimulan respuestas inmunológicas anti-tumorales o para estimular células T ex vivo y transferirlas a los pacientes. Los péptidos unidos a moléculas del complejo mayor de histocompatibilidad (MHC), o péptidos semejantes, también pueden ser blancos de anticuerpos, receptores de células T solubles y otras moléculas de unión.
ARP180100893A 2017-04-10 2018-04-10 Péptidos y combinaciones de los mismos para usar en una inmunoterapia contra cánceres AR111459A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762483702P 2017-04-10 2017-04-10

Publications (1)

Publication Number Publication Date
AR111459A1 true AR111459A1 (es) 2019-07-17

Family

ID=67439454

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP180100893A AR111459A1 (es) 2017-04-10 2018-04-10 Péptidos y combinaciones de los mismos para usar en una inmunoterapia contra cánceres

Country Status (2)

Country Link
AR (1) AR111459A1 (es)
EA (2) EA202191120A3 (es)

Also Published As

Publication number Publication date
EA202191120A2 (ru) 2021-08-31
EA202191120A3 (ru) 2022-01-31
EA201992417A1 (ru) 2020-02-20

Similar Documents

Publication Publication Date Title
CL2023001346A1 (es) Uso de péptidos en inmunoterapia contra cáncer de pulmón amicrocítico y otros.
CO2018010284A2 (es) Tratamientos contra el cáncer de útero
PE20230768A1 (es) Nuevos peptidos y nuevas combinaciones de peptidos para el uso en la inmunoterapia contra el cancer de pulmon, incluido el cancer de pulmon amicrocitico y otros tipos de cancer
CR20180398A (es) Péptidos, combinaciones de péptidos y células para el uso en la inmunoterapia contra el cáncer de vejiga y otros tipos de cáncer
CR20180422A (es) PÉPTIDOS Y COMBINACIÓN DE PÉPTIDOS NOVEDOSOS PARA SU USO EN INMUNOTERAPIA CONTRA DIVERSOS TUMORES (DIivisional 2017-0522)
CO2019008008A2 (es) Nuevos péptidos y nuevas combinaciones de péptidos para el uso en la inmunoterapia contra el cáncer de ovario y otros tipos de cáncer
CL2020002123A1 (es) Péptidos y combinación de péptidos de origen no canónico para el uso en la inmunoterapia contra diferentes tipos de cáncer.
CL2021000979A1 (es) Nuevos péptidos y combinación de péptidos para usar en inmunoterapia contra el cáncer esofágico y otros cánceres. (divisional de la solicitud no. 201703361)
CO2019012077A2 (es) Péptidos y combinaciones de los mismos para el uso en la inmunoterapia contra diversos tipos de cáncer
CO2021000534A2 (es) Inmunoterapia con péptidos restringidos a b*07 y una combinación de péptidos contra el cáncer y métodos relacionados
CO2017009922A2 (es) Péptidos y combinación de péptidos para inmunoterapia contra diversos tumores
CL2024000530A1 (es) Péptidos y combinaciones, su uso en la inmunoterapia contra cáncer de pulmón y otros cánceres
CO2019012071A2 (es) Péptidos y combinaciones de péptidos para el uso en la inmunoterapia contra la leucemia y otros tipos de cáncer
AR112331A1 (es) Péptidos y combinaciones de péptidos para el uso en la inmunoterapia contra el cáncer de pulmón, incluyendo el nsclc, el sclc y otros cánceres
CO2021003404A2 (es) Inmunoterapia con péptidos restringidos a a*01 y una combinación de péptidos contra el cáncer y métodos relacionados
CL2023001324A1 (es) Péptidos, combinaciones, células para inmunoterapia contra cáncer de vejiga y otros cánceres
CL2020002935A1 (es) Péptidos para el uso en la inmunoterapia contra el cáncer
CL2021001336A1 (es) Inmunoterapia con péptidos restringidos a b*08 y una combinación de péptidos contra el cáncer y métodos relacionados
CO2017009101A2 (es) Péptidos y combinación de péptidos
CL2017002766A1 (es) Nuevos péptidos y nuevas combinaciones de péptidos y de soportes para el uso en la inmunoterapia contra el carcinoma colorrectal y otros tipos de cáncer
AR111459A1 (es) Péptidos y combinaciones de los mismos para usar en una inmunoterapia contra cánceres
AR111370A1 (es) Péptidos y combinaciones de péptidos para usar en inmunoterapias contra leucemias y otros cánceres
AR124243A2 (es) Péptidos para usar en inmunoterapia contra el cáncer esofágico y otros cánceres
AR117437A1 (es) Inmunoterapia con péptidos restringidos a b*08 y una combinación de péptidos contra el cáncer y métodos relacionados
AR115881A1 (es) Inmunoterapia con péptidos restringidos a b*07 y una combinación de péptidos contra el cáncer y métodos relacionados